Welcome to our dedicated page for Arrowhead Pharma SEC filings (Ticker: ARWR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arrowhead Pharmaceuticals filings document regulatory disclosures for a commercial-stage RNAi therapeutics company with common stock registered on the Nasdaq Global Select Market. Form 8-K reports furnish fiscal results, Regulation FD clinical-data presentations, material agreements and capital-structure updates, including disclosures tied to convertible senior notes.
Proxy and annual-meeting filings cover board elections, executive-compensation votes, incentive-plan approvals and auditor ratification. The filing record also documents securityholder voting outcomes, governance matters, and disclosures related to programs such as REDEMPLO, ARO-INHBE and ARO-ALK7, alongside the company’s RNAi platform, development pipeline and commercial activities.
Arrowhead Pharmaceuticals filed a Schedule 13G reporting that FMR LLC beneficially owned 7,349,106.75 shares of common stock, representing 5.2% of the class as shown in the filing. The cover shows sole voting power of 7,323,647.12 and sole dispositive power of 7,349,106.75. The filing lists an Exhibit referencing a related 13d-1(k)(1) agreement.
Arrowhead Pharmaceuticals disclosure: Vanguard Capital Management reports beneficial ownership of 7,081,293 shares of Common Stock, representing 5.05% of the class. The filer reports sole voting power for 1,048,877 shares and sole dispositive power for 7,081,293 shares. The filing is signed on 04/29/2026.
Arrowhead Pharmaceuticals Inc ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 7,269,957 shares of common stock, representing 5.19% of the class. The filing states Vanguard has sole dispositive power over these shares and sole voting power over 123,821 shares. The holdings include securities held for Vanguard funds and managed accounts.
Arrowhead Pharmaceuticals’ Chief Financial Officer Daniel Joseph Apel sold 13,095 shares of common stock on April 22, 2026 in open-market transactions. The sales occurred at weighted average prices ranging from about $69.50 to $71.97 per share under a pre-established Rule 10b5-1 trading plan.
Following these sales, Apel directly holds 162,905 shares of Arrowhead common stock, which includes shares underlying previously reported restricted stock units that remain subject to vesting conditions. A portion of the disposition was made to satisfy tax withholding obligations related to equity compensation.
Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, sold 10,000 shares of common stock in an open-market transaction at a weighted average price of $75.00 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan. Following this sale, Hamilton directly holds 226,958 shares, including shares underlying Restricted Stock Units, some of which remain subject to vesting conditions.
Arrowhead Pharmaceuticals reports that BlackRock, Inc. beneficially owned 17,104,084 shares of Common Stock, representing 12.2% of the class as of 03/31/2026. The filing states BlackRock has sole voting power for 16,769,679 shares and sole dispositive power for 17,104,084 shares. The filing is an amendment (No. 5) to a Schedule 13G/A and is signed by a BlackRock managing director on 04/24/2026.
James Hamilton reported proposed sales of Common Stock under Rule 144. The filing lists an aggregate proposed sale of 10,000 shares and subdivided lots of 5,708, 542, 1,628, and 2,122 dated 01/04/2026. The filing also shows a prior sale of 10,000 shares on 03/05/2026 for $641,870.05.
The Vanguard GroupSchedule 13G/A reporting its holdings in Arrowhead Pharmaceuticals Inc.. The filing states amount beneficially owned: 0 shares and percent of class: 0%. It explains an internal realignment on January 12, 2026 and that certain Vanguard subsidiaries now report holdings separately, in accordance with SEC Release No. 34-39538 (January 12, 1998).
Arrowhead Pharmaceuticals reported results of its 2026 annual stockholder meeting. Stockholders elected seven directors to the board, with vote totals for each nominee ranging from about 70.4 million to 100.8 million votes in favor.
Stockholders rejected the advisory Say-on-Pay proposal, with 41,625,740 votes for and 59,963,903 votes against, signaling dissatisfaction with executive compensation. They approved the Amended and Restated 2021 Incentive Plan and ratified KPMG LLP as independent auditors. As of the January 22, 2026 record date, 140,010,690 common shares were outstanding and entitled to vote.